In addition, targeting the low-density lipoprotein receptor (LDLR) with an integrated AAV-CRISPR vector and liver-directed destruction of LDLR was demonstrated to be a viable and reliable alternative way to study atherosclerosis (115, 116). This evidence concerns the gene LDLR and atherosclerosis.